- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07580326
Microplastics in Brain Hematomas and Neurological Outcomes After Intracerebral Hemorrhage (PARTENOPE)
Plastic Accumulation in Residual Brain Tissues From Hemorrhagic Events: Neurological Outcomes and Pathogenetic Evidence (PARTENOPE Study)
This observational study investigates the presence of micro- and nanoplastics in surgically removed intracerebral hematomas and their association with neurological outcomes in patients with spontaneous intracerebral hemorrhage.
Microplastics have recently been identified in human tissues and are increasingly recognized as potential contributors to inflammation and vascular dysfunction. However, their role in cerebrovascular diseases, particularly intracerebral hemorrhage, remains unknown.
Patients undergoing surgical hematoma evacuation will be enrolled. Brain tissue and blood samples will be analyzed using advanced spectroscopic and imaging techniques to detect and characterize micro- and nanoplastics.
The study aims to evaluate whether the presence of these particles is associated with increased inflammation, worse neurological outcomes, and higher risk of adverse cerebrovascular events.
This research may provide novel insights into the impact of environmental pollutants on brain vascular disease and patient prognosis.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Spontaneous intracerebral hemorrhage is a severe and life-threatening neurological condition representing approximately 10-15% of all strokes worldwide and is associated with high early mortality and substantial long-term disability. Despite significant advances in neuroimaging, neurosurgical techniques, and neurocritical care, clinical outcomes remain poor, and the biological mechanisms underlying hemorrhage initiation, expansion, and secondary brain injury are still incompletely understood.
The pathophysiology of intracerebral hemorrhage is characterized by a complex interplay of vascular, inflammatory, and neurotoxic processes. Structural vascular alterations, endothelial dysfunction, and disruption of the blood-brain barrier contribute to vessel rupture and hematoma formation. Following the initial bleeding event, secondary brain injury is driven by hematoma-induced mechanical damage, oxidative stress, activation of resident and infiltrating immune cells, and release of pro-inflammatory mediators. Microglial activation, macrophage infiltration, and inflammasome-related pathways are recognized as important contributors to neuronal injury and neurological deterioration.
While traditional risk factors such as hypertension and small vessel disease are well established, the contribution of environmental exposures to cerebrovascular vulnerability has been largely overlooked. In recent decades, environmental exposure to micro- and nanoplastics has emerged as a global health concern. The exponential increase in plastic production has resulted in widespread distribution of plastic-derived particles across ecosystems, leading to chronic human exposure through ingestion, inhalation, and dermal contact.
Microplastics and nanoplastics have been detected in multiple biological matrices, including blood, lung tissue, placenta, and cardiovascular structures. Experimental and translational studies suggest that these particles may interact with biological systems by promoting oxidative stress, immune activation, endothelial dysfunction, and tissue inflammation. Microplastics and nanoplastics have also been described in vascular tissues, supporting the rationale for investigating their potential association with cerebrovascular disease.
The central nervous system is particularly susceptible to vascular and inflammatory insults, and preservation of blood-brain barrier integrity plays a critical role in maintaining neural homeostasis. Emerging evidence indicates that nanoscale particles may cross biological barriers and potentially contribute to neuroinflammation, microglial activation, and neuronal dysfunction. However, the presence, distribution, and potential biological impact of microplastics and nanoplastics in cerebrovascular diseases, particularly intracerebral hemorrhage, have not been systematically investigated.
The PARTENOPE study (Plastic Accumulation in Residual Brain Tissues from Hemorrhagic Events: Neurological Outcomes and Pathogenetic Evidence) has been designed to address this knowledge gap. This observational cohort study integrates retrospective and prospective data collection and adopts a translational approach combining clinical characterization, advanced analytical chemistry, and biological investigation.
Study Design and Population
The study includes adult patients diagnosed with spontaneous intracerebral hemorrhage undergoing neurosurgical hematoma evacuation. Both retrospectively identified cases and prospectively enrolled patients are included to capture a broad spectrum of clinical presentations and improve the robustness and generalizability of findings.
Patients with traumatic intracranial hemorrhage, intracranial neoplasms, or vascular malformations are excluded to ensure a homogeneous population focused on primary spontaneous hemorrhagic events.
Biological Sample Collection and Contamination Control
Intracerebral hematoma samples are collected intraoperatively using standardized protocols specifically designed to minimize environmental contamination. Measures include the use of non-plastic surgical instruments, glass collection systems, and controlled laboratory environments to preserve sample integrity and minimize external contamination.
Peripheral blood samples are obtained to assess systemic exposure to microplastics and nanoplastics and to enable comparative analyses between circulating and tissue-associated particle burden.
Analytical Characterization of Microplastics and Nanoplastics
Identification and characterization of microplastics and nanoplastics are performed using a multimodal analytical platform integrating advanced spectroscopic and imaging techniques. These techniques include scanning electron microscopy with energy-dispersive X-ray spectroscopy, Fourier-transform infrared spectroscopy, Raman spectroscopy, and pyrolysis gas chromatography-mass spectrometry.
This integrated analytical approach enables high-resolution characterization of particle size, morphology, and polymer composition. Quantitative analyses provide estimates of particle burden within hematoma tissue, while qualitative analyses identify polymer types and potential environmental sources.
Spatial mapping analyses are also conducted to determine localization of particles within the hematoma matrix, including their presence in extracellular compartments and their potential interaction with inflammatory cells such as macrophages.
Clinical and Radiological Characterization
Comprehensive clinical data are collected, including demographic variables, cardiovascular risk factors, medication exposure, and comorbid conditions. Radiological assessment includes hematoma volume, location, and imaging characteristics derived from computed tomography and magnetic resonance imaging.
Perioperative variables, surgical techniques, and postoperative management are also recorded to enable integrated analysis of clinical and biological determinants of outcome.
Outcome Assessment
Patients are followed longitudinally to evaluate neurological and clinical outcomes using standardized clinical, radiological, and biological assessments.
Primary and Secondary Objectives
The primary objective of the study is to evaluate the presence and burden of microplastics and nanoplastics in intracerebral hematoma tissue and to investigate their association with neurological and cerebrovascular outcomes.
Secondary objectives include:
- evaluating the relationship between circulating and tissue-associated particle levels
- assessing the association between particle burden and inflammatory responses
- exploring the potential contribution of microplastics and nanoplastics to hematoma progression and recurrence
- characterizing the physicochemical properties and distribution of detected particles
Mechanistic and Exploratory Analyses
Exploratory analyses aim to investigate potential mechanistic pathways linking microplastic and nanoplastic exposure to neurovascular injury. These include evaluation of oxidative stress pathways, immune cell activation, endothelial dysfunction, and inflammatory signaling cascades.
Particular attention is given to macrophage activation, microglial response, and inflammasome-related pathways that may contribute to secondary brain injury after hemorrhage. The interaction between microplastics and nanoplastics and the blood-brain barrier is also explored, including their potential contribution to barrier dysfunction and increased vascular permeability.
Scientific and Clinical Implications
The PARTENOPE study represents one of the first systematic investigations of microplastics and nanoplastics in intracerebral hemorrhage. By integrating environmental exposure science with clinical neurology and advanced analytical techniques, this study aims to provide novel insights into the potential role of environmental pollutants in cerebrovascular disease.
If an association between microplastic and nanoplastic accumulation and adverse clinical outcomes is identified, these findings may have important implications for risk stratification, prevention strategies, and future research on environmental determinants of neurological disease.
Ultimately, this study seeks to contribute to a more comprehensive understanding of the factors influencing cerebrovascular health and disease progression.
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
-
Naples, Itália, 80138
- University Hospital Luigi Vanvitelli
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Age ≥18 years
- Diagnosis of spontaneous intracerebral hemorrhage confirmed by CT or MRI
- Indication for surgical hematoma evacuation
- Availability of intracerebral hematoma tissue sample
- Ability to provide informed consent (patient or legal representative)
Exclusion Criteria:
- Traumatic intracerebral hemorrhage
- Intracranial neoplasms
- Known vascular malformations (e.g., arteriovenous malformations, aneurysms)
- Severe systemic infection or sepsis at admission
- Inadequate or contaminated biological samples
- Refusal or inability to provide informed consent
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Intracerebral Hemorrhage Patients
Patients with spontaneous intracerebral hemorrhage undergoing surgical hematoma evacuation.
Micro- and nanoplastics will be measured in hematoma tissue and blood samples, and associations with clinical outcomes will be evaluated.
|
No intervention is administered as part of the study.
All patients receive standard clinical care according to current guidelines for intracerebral hemorrhage.
Biological samples, including intracerebral hematoma tissue and peripheral blood, are collected for observational analysis of micro- and nanoplastics and their association with clinical, radiological, and biological outcomes.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Concentration of Micro- and Nanoplastics in Intracerebral Hematoma Tissue
Prazo: Baseline (intraoperative sampling)
|
Quantification of micro- and nanoplastics in intracerebral hematoma tissue samples collected during surgical evacuation.
|
Baseline (intraoperative sampling)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Modified Rankin Scale Score
Prazo: 12 months
|
Neurological outcome assessed using the modified Rankin Scale, a 7-point functional outcome scale ranging from 0 (no symptoms) to 6 (death), where higher scores indicate worse neurological disability.micro- and nanoplastic burden.
|
12 months
|
|
Circulating Concentrations of Inflammatory Biomarkers
Prazo: Baseline
|
Measurement of circulating inflammatory biomarkers, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), and their association with micro- and nanoplastics.hematoma
tissue samples collected during surgical evacuation.
Neurological outcome will be assessed using the modified Rankin Scale (mRS), a 7-point functional outcome scale ranging from 0 (no symptoms) to 6 (death), where higher scores indicate worse neurological disability.
|
Baseline
|
|
Concentration of Circulating Micro- and Nanoplastics
Prazo: Baseline
|
Concentration of circulating micro- and nanoplastics measured in peripheral blood samples and evaluated in relation to micro- and nanoplastic burden in intracerebral hematoma tissue.
|
Baseline
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Hematoma Volume
Prazo: Baseline
|
Measurement of intracerebral hematoma volume assessed by CT imaging and its association with micro- and nanoplastic burden.
|
Baseline
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Publicações Gerais
- Prattichizzo F, Ceriello A, Pellegrini V, La Grotta R, Graciotti L, Olivieri F, Paolisso P, D'Agostino B, Iovino P, Balestrieri ML, Rajagopalan S, Landrigan PJ, Marfella R, Paolisso G. Micro-nanoplastics and cardiovascular diseases: evidence and perspectives. Eur Heart J. 2024 Oct 7;45(38):4099-4110. doi: 10.1093/eurheartj/ehae552.
- Marfella R, Kallweit U. Neurotoxicity at the Tides: A Call to Action on Marine Microplastics and Brain Health. Eur J Neurol. 2025 May;32(5):e70181. doi: 10.1111/ene.70181. No abstract available.
- Marfella R, Prattichizzo F, Paolisso G. Microplastics and nanoplastics: tiny threats for cardiovascular diseases? Cardiovasc Res. 2025 Oct 24;121(12):1793-1795. doi: 10.1093/cvr/cvaf143. No abstract available.
- Marfella R, Carreras F, Prattichizzo F, La Grotta R, Pellegrini V, Sardu C, D'Onofrio N, Barbieri M, Municino M, Siniscalchi M, Spinetti F, Vigliotti G, Vecchione C, Carrizzo A, Accarino G, Squillante A, Spaziano G, Mirra D, Esposito R, Fenti A, Galoppo S, Canzano S, Marfella LV, Falco G, Balestrieri ML, Mauro C, Ceriello A, Landrigan PJ, D'Agostino B, Iovino P, Paolisso G. Detection and Proinflammatory Effects of BTEX within the Human Atherosclerotic Plaque. Environ Sci Technol. 2025 Dec 23;59(50):27044-27056. doi: 10.1021/acs.est.5c04941. Epub 2025 Dec 11.
- D'Onofrio N, Donisi I, Del Vecchio V, Prattichizzo F, Pellegrini V, Barbieri M, Ceriello A, Marfella R, Paolisso G, Balestrieri ML. PCSK9 inhibition ameliorates microplastic-induced endothelial redox imbalance via SIRT6 modulation. Cell Mol Biol Lett. 2025 Dec 22;31(1):9. doi: 10.1186/s11658-025-00838-z.
- Marfella R, Prattichizzo F, Barbieri M, Paolisso P, Scisciola L, Basilicata MG, Marfella LV, Pesapane A, Fenti A, La Grotta R, Carreras F, Iovino P, Barbato E, Ceriello A, Landrigan PJ, Paolisso G. Microplastics and Atherosclerosis: Mechanisms. Annu Rev Pharmacol Toxicol. 2026 Jan;66(1):369-390. doi: 10.1146/annurev-pharmtox-062124-113011.
- Donisi I, Sardu C, Colloca A, Balestrieri A, Vecchio VD, Marfella R, Campanile G, D'Onofrio N, Balestrieri ML. In vitro evidence and integrative bioinformatics identify the SGLT2-PPARgamma axis as a target against polyethylene microplastic-driven metabolic reprogramming in colorectal cancer cells. J Transl Med. 2026 Feb 2;24(1):312. doi: 10.1186/s12967-026-07776-0.
- Prattichizzo F, Paolisso G, Iovino P, Marfella R. Microplastics and nanoplastics: Novel components of the environmental exposome associated with cardiovascular diseases. Trends Cardiovasc Med. 2026 Mar 12:S1050-1738(26)00038-1. doi: 10.1016/j.tcm.2026.03.003. Online ahead of print. No abstract available.
- Marfella R, Fumagalli C, Marfella LV, Furbatto F, Fenti A, Paolisso P, Sardu C, Prattichizzo F, Iovino P, Mauro C. Environmental Pollutant-Induced Cardiopathogenesis Through Immune Dysfunction: The Emerging Role of Micro- and Nanoplastics. Can J Cardiol. 2026 Apr 8:S0828-282X(26)00300-4. doi: 10.1016/j.cjca.2026.03.050. Online ahead of print.
- Leslie HA, van Velzen MJM, Brandsma SH, Vethaak AD, Garcia-Vallejo JJ, Lamoree MH. Discovery and quantification of plastic particle pollution in human blood. Environ Int. 2022 May;163:107199. doi: 10.1016/j.envint.2022.107199. Epub 2022 Mar 24.
- Marfella R, Prattichizzo F, Sardu C, Fulgenzi G, Graciotti L, Spadoni T, D'Onofrio N, Scisciola L, La Grotta R, Frige C, Pellegrini V, Municino M, Siniscalchi M, Spinetti F, Vigliotti G, Vecchione C, Carrizzo A, Accarino G, Squillante A, Spaziano G, Mirra D, Esposito R, Altieri S, Falco G, Fenti A, Galoppo S, Canzano S, Sasso FC, Matacchione G, Olivieri F, Ferraraccio F, Panarese I, Paolisso P, Barbato E, Lubritto C, Balestrieri ML, Mauro C, Caballero AE, Rajagopalan S, Ceriello A, D'Agostino B, Iovino P, Paolisso G. Microplastics and Nanoplastics in Atheromas and Cardiovascular Events. N Engl J Med. 2024 Mar 7;390(10):900-910. doi: 10.1056/NEJMoa2309822.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Distúrbios Cerebrovasculares
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Doenças Vasculares
- Doenças cardiovasculares
- Processos Patológicos
- Hemorragia
- Inflamação
- Hemorragias Intracranianas
- Condições Patológicas, Sinais e Sintomas
- Doenças Neuroinflamatórias
- Hemorragia cerebral
Outros números de identificação do estudo
- PARTENOPE-ICH-01
- DAMSS-CIAMC-2026 (Número de outro subsídio/financiamento: University of Campania "Luigi Vanvitelli",)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Prazo de Compartilhamento de IPD
Critérios de acesso de compartilhamento IPD
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .